Want to see WALD full AI Analyst Report?
WALD Stock Chart & Stats
$1.69
<$0.01(0.30%)
At close: 4:00 PM EDT
$1.69
<$0.01(0.30%)
Day’s Range― - ―
52-Week Range$0.72 - $3.22
Previous CloseN/A
Volume288.82K
Average Volume (3M)145.38K
Market Cap
$226.26M
Enterprise Value$377.59
Total Cash (Recent Filing)$31.89M
Total Debt (Recent Filing)$149.01M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding120,766,580
10 Day Avg. Volume133,325
30 Day Avg. Volume145,381
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.79
P/FCF Ratio-13.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.50Price Target Upside47.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$297.14M
Bulls Say, Bears Say
Bulls Say
Balance-sheet FlexibilityManageable leverage and a sizable equity base provide durable financial flexibility. Lower absolute debt in 2025 reduces refinancing risk and gives management room to fund operations or M&A without immediate distress, supporting platform stability while profitability recovers.
Proceeds-driven De‑leveraging (Obagi Sale)The planned Obagi divestiture materially strengthens liquidity and reduces secured debt, lowering funding risk and interest burden. This creates a durable capital reset that can support reinvestment in core Milk Makeup or reduce reliance on external financing over the medium term.
Regulatory Overhang RemovedClosure of the SEC inquiry eliminates a multi-year governance and reporting overhang, improving transparency and lowering legal/regulatory uncertainty. This strengthens long-term stakeholder confidence and eases potential friction in capital markets and commercial partnerships.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow indicate the business is not yet self-funding. Continued cash burn requires refinancing, asset sales or equity raises, constraining the ability to consistently invest in marketing, product development and distribution over the next several quarters.
Sustained UnprofitabilityRepeated negative EBIT and widening net losses show the operating model has not reached sustainable margins. Without structural margin improvement or cost discipline, returns on capital will remain poor, eroding shareholder value and limiting reinvestment capacity over the medium term.
Loss Of Fast-growing Asset And Founder ExitsDivesting Obagi removes a fast-growing, physician-led megabrand and triggers founder departures, reducing scale and diversification. Although proceeds help liquidity, Waldencast will face concentration risk around Milk Makeup and must rebuild growth engines without the sold business and its leadership.
Waldencast News
WALD FAQ
What was Waldencast’s price range in the past 12 months?
Waldencast lowest stock price was $0.72 and its highest was $3.22 in the past 12 months.
What is Waldencast’s market cap?
Waldencast’s market cap is $226.26M.
When is Waldencast’s upcoming earnings report date?
Waldencast’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Waldencast’s earnings last quarter?
Waldencast released its earnings results on May 26, 2026. The company reported -$0.171 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.024.
Is Waldencast overvalued?
According to Wall Street analysts Waldencast’s price is currently Undervalued.
Does Waldencast pay dividends?
Waldencast does not currently pay dividends.
What is Waldencast’s EPS estimate?
Waldencast’s EPS estimate is -0.26.
How many shares outstanding does Waldencast have?
Waldencast has 120,766,580 shares outstanding.
What happened to Waldencast’s price movement after its last earnings report?
Waldencast reported an EPS of -$0.171 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Waldencast?
Currently, no hedge funds are holding shares in WALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Waldencast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (47.93% Upside)
$2.50 (47.93% Upside)
Blogger Sentiment
Bullish
WALD Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.36%
Trailing 12-Months
Company Description
Waldencast
Waldencast Plc develops and operates a beauty and wellness platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It intends to seek brands with a direct connection to consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. The company was founded by Michel Brousset and Hind Sebti on December 8, 2020 and is headquartered in White Plains, NY.
WALD Stock 12 Month Forecast
Average Price Target
$2.50
▲(47.93% Upside)
Technical Analysis
Nu Skin
―
e.l.f. Beauty
―
Yatsen Holding
―
Honest Company
―
Grove Collaborative Holdings
―
Ownership Overview
―
Insiders
0.95% Mutual Funds
2.09% Other Institutional Investors
96.96% Public Companies and
Individual Investors